This Article Full Text Full Text (PDF) All Versions of this Article: 40/4/1405    most recent STROKEAHA.108.534107v1 Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Amarenco, P. Search for Related Content PubMed PubMed Citation Articles by Amarenco, P. Pubmed/NCBI databases Compound via MeSH Substance via MeSH Hazardous Substances DB ATORVASTATIN HEPTANOIC ACID PYRROLE Medline Plus Health Information Cholesterol Stroke Related Collections Lipids Transient Ischemic Attacks Lipid and lipoprotein metabolism

(Stroke. 2009;40:1405.)
© 2009 American Heart Association, Inc.

Original Contributions

Results of the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) Trial by Stroke Subtypes

Pierre Amarenco, MD; Oscar Benavente, MD; Larry B. Goldstein, MD; Alfred Callahan, III, MD; Henrik Sillesen, MD, DMSc; Michael G. Hennerici, MD, PhD; Steve Gilbert, PhD; Amy E. Rudolph, PhD; Lisa Simunovic, MS; Justin A. Zivin, MD, PhD; K. Michael A. Welch, MB, ChB, FRCP on behalf of the SPARCL Investigators

From INSERM U-698 and Denis Diderot University (P.A.), Paris, France; the University of Texas Health Science Center (O.B.), San Antonio; Duke University (L.B.G.), Durham, North Carolina; Vanderbilt University (A.C.), Nashville, Tenn; University of Copenhagen (H.S.), Denmark; University of Heidelberg (M.G.H.), Mannheim, Germany; Rho Inc (S.G.), Newton, Mass; Pfizer Inc (A.E.R., L.S.), New York; University of San Diego (J.A.Z.), Calif; and Rosalind Franklin University (K.M.A.W.), Chicago, Ill.

Correspondence to Dr Amarenco, INSERM U-698 and Denis Diderot University-Paris VII, Department of Neurology and Stroke Centre, Bichat University Hospital, 46, rue Henri Huchard, 75018, Paris, France. E-mail pierre.amarenco{at}bch.aphp.fr

Background and Purpose— The SPARCL trial showed that atorvastatin 80 mg/d reduces the risk of stroke and other cardiovascular events in patients with recent stroke or transient ischemic attack (TIA). We tested the hypothesis that the benefit of treatment varies according to index event stroke subtype.

Methods— Subjects with stroke or TIA without known coronary heart disease were randomized to atorvastatin 80 mg/d or placebo. The SPARCL primary end point was fatal or nonfatal stroke. Secondary end points included major cardiovascular events (MCVE; stroke plus major coronary events). Cox regression models testing for an interaction with treatment assignment were used to explore potential differences in efficacy based on stroke subtype.

Results— For subjects randomized to atorvastatin versus placebo, a primary end point occurred in 13.1% versus 18.6% of those classified as having large vessel disease (LVD, 15.8% of 4,731 participants), in 13.1% versus 15.5% of those with small vessel disease (SVD, 29.8%), in 11.2% versus 12.7% of those with ischemic stroke of unknown cause (21.5%), in 7.6% versus 8.8% of those with TIA (30.9%), and in 22.2% versus 8.3% of those with hemorrhagic stroke (HS, 2%) at baseline. There was no difference in the efficacy of treatment for either the primary end point (LVD hazard ratio [HR] 0.70, 95% confidence interval [CI] 0.49 to 1.02, TIA HR 0.81, CI 0.57 to 1.17, SVD HR 0.85, CI 0.64 to 1.12, unknown cause HR 0.87, CI 0.61 to 1.24, HS HR 3.24, CI 1.01 to 10.4; P for heterogeneity=0.421), or MCVEs (P for heterogeneity=0.360) based on subtype of the index event. As compared to subjects with LVD strokes, those with SVD had similar MCVE rates (19.2% versus 18.5% over the course of the trial), and similar overall reductions in stroke and MCVEs.

Conclusions— Atorvastatin 80 mg/d is similarly efficacious in preventing strokes and other cardiovascular events, irrespective of baseline ischemic stroke subtype.

Key Words: stroke • transient ischemic attack • statins, cholesterol

This article has been cited by other articles:

				A. A. Rabinstein Statins Prevent Stroke Recurrences... But Can They Improve Stroke Outcome? Stroke, November 1, 2009; 40(11): 3413 - 3414. [Full Text] [PDF]

				D Fiorella, T N Turan, C P Derdeyn, and M I Chimowitz Current status of the management of symptomatic intracranial atherosclerotic disease: the rationale for a randomized trial of medical therapy and intracranial stenting JNIS, July 3, 2009; (2009) jnis.2009.000125v1. [Abstract] [Full Text] [PDF]